ОбзорГрафикТехническийНовостиTraderScreen

Tenax Therapeutics Inc/  US88032L6056  /

NASDAQ
15.11.2024  22:00:00 Изменение -0.0700 Объем сделки Бид1:55:44 Предложение1:55:44 Максимум Минимум
4.8700USD -1.42% 44,852
Оборот: 197,847.3316		 4.7500Величина цены спроса: 100 5.0000Величина цены предложения: 300 5.0000 4.8600
GlobeNewswire 13.08 Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 12.08 Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the O...
GlobeNewswire 06.08 Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
GlobeNewswire 14.05 Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 30.04 Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertens...
GlobeNewswire 09.04 Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a...
GlobeNewswire 28.03 Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ...
GlobeNewswire 12.03 Tenax Therapeutics to Present at the 36th Annual Roth Conference
GlobeNewswire 29.02 Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT ...
GlobeNewswire 20.02 Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimen...
GlobeNewswire 08.02 Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
GlobeNewswire 08.02 Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimenda...
GlobeNewswire 06.02 Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significa...
GlobeNewswire 29.12.2023 Tenax Therapeutics Announces Reverse Stock Split
GlobeNewswire 17.11.2023 Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific ...
GlobeNewswire 13.11.2023 Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment ...
GlobeNewswire 31.01.2022 Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
GlobeNewswire 04.01.2022 Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
GlobeNewswire 06.12.2021 Avalo Appoints Two New Independent Directors to Its Board
GlobeNewswire 05.04.2018 Artificial Blood and Plasma 2018 - Global Markets to 2027
GlobeNewswire 26.04.2017 Orion Group Interim Report January-March 2017
GlobeNewswire 08.02.2017 Orion Group Financial Statement Release for 2016
GlobeNewswire 25.10.2016 Orion Group Interim Report January-September 2016
GlobeNewswire 19.07.2016 Orion Group Half-Yearly Report January-June 2016
GlobeNewswire 27.04.2016 Orion Group Interim Report January-March 2016